Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and composition for treatment of inflammatory pain

A technology for inflammatory pain and inflammatory process, applied in the field of relieving, treating inflammatory pain, reducing or otherwise improving the symptoms, prevention, and treatment of inflammatory pain, and can solve problems such as weak effect and slow effect

Inactive Publication Date: 2009-07-15
CNSBIO PTY LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Finally, other compounds such as taurine chondroitin, diacerein, and glucosamine sulfate have shown beneficial effects in improving inflammatory pain associated with joint tissue degeneration, but these compounds are slow acting and less effective in treating inflammatory pain than Weak effect of NSAIDS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and composition for treatment of inflammatory pain
  • Methods and composition for treatment of inflammatory pain
  • Methods and composition for treatment of inflammatory pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0197] Use of NK1 antagonists in the treatment of pain

[0198] Experiments were performed using male Wistar rats (weight 150 to 220 g). Three series of experiments were conducted in an observer-blind manner, including saline (negative) control and gabapentin (GABAPentin) (positive) control. The research is divided into three phases:

[0199] 1. Tested the sedation of aprepitant (an example of NK antagonist) alone and in combination with flupirtine (an example of a neuroexcitatory inhibitor) over a range of doses using an open field activity monitor Effect. This approach determines the doses of drugs and drug combinations that can be used for analgesic effects that do not cause sedation;

[0200] 2. To test the ability of aprepitant administered alone and in combination with flupirtine in a range of doses to reverse the allodynia effect induced by plantar injection of carrageenan;

[0201] 3. To test the ability of aprepitant administered alone and in combination with flup...

Embodiment 2

[0215] Compound Screening in In Vivo Models

[0216] The animal experimental model of pain caused by inflammation in humans is carrageenan paw inflammation in rats. Plantar injection of carrageenan into the pad of one hind paw of male Wistar rats resulted in inflammation and swelling of the hind paw over a three hour period. This causes a decrease in paw pressure paw retraction threshold. Injury tolerance was measured in the normal rat hind paw and in the inflammatory hind paw of carrageenan-treated rats, using a noxious stimulus such as the heat-flash-foot test, to measure paw retraction; or using calibrated Von Frey fibers as a stimulus, to measure Paw retraction of pressure applied to the inflamed paw. The key points shown by these results are:

[0217] 1. The maximum non-sedating dose of each drug. Rats were first administered a range of drug doses, followed by assessment of sedation using two tests: the outdoor exploration and the rota-rod test.

[0218] 2. Using carr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor.

Description

technical field [0001] The present invention relates generally to the field of pain management, especially the management of inflammatory pain, without causing overt sedation. More particularly, the present invention provides methods, procedures, compositions and devices for treating, alleviating, preventing, attenuating or otherwise ameliorating the symptoms of inflammatory pain. Background technique [0002] Details related to the bibliography of references provided by the subject specification are listed at the end of the specification. [0003] Any reference to prior art in this specification is not, and should not be taken as, an affirmation or implication that such prior art forms part of the public general knowledge in any country. [0004] Inflammatory pain results from damage to tissue integrity at the cellular level. It can be associated with penetrating trauma, burns, extreme frostbite, bone fractures, arthritis, autoimmune conditions, excessive strain, infectio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/44A61K31/5377A61K31/196A61P29/00
CPCA61K31/196A61K31/5377A61K31/44A61P1/02A61P1/04A61P11/00A61P13/02A61P17/10A61P19/02A61P25/00A61P25/04A61P27/16A61P29/00A61P31/16A61P43/00
Inventor C·S·古德柴尔德
Owner CNSBIO PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products